SCHEMBL22796194

SCHEMBL22796194

O=C(CCc1ccc(O)cc1)CC(CCc1ccc(O)c(O)c1)OC1CC[C@@H](O)C(O)C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 1/20 0.40
▸ PPARD Q03181 1/20 0.40
▸ PPARA Q07869 1/20 0.40
▸ IAPP P10997 3/20 0.40
▸ CCR5 P51681 2/20 0.40
▸ POLB P06746 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ LMNA P02545 2/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ MAPK1 P28482 2/20 0.38
▸ CYP3A4 P08684 2/20 0.38
▸ IGF1R P08069 1/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ SLC22A1 O15245 1/20 0.38
▸ CA12 O43570 1/20 0.38
▸ EGFR P00533 1/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ LCK P06239 1/20 0.38
▸ FYN P06241 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22796193 0.85 PPARG (0.42) PPARGPPARDPPARAIAPPCCR5
Alnuside B SCHEMBL22796510 0.80 PPARG (0.49) PPARGPPARDPPARAIAPPPOLB
Alnuside B SCHEMBL12672476 0.80 PPARG (0.49) PPARGPPARDPPARAIAPPPOLB
SCHEMBL14790109 0.78 IAPP (0.52) IAPPPOLBGAALMNAKDM4E
Oregonin SCHEMBL29389089 0.76 PPARG (0.46) PPARGPPARDPPARAIAPPCCR5
Oregonin SCHEMBL12659728 0.76 PPARG (0.46) PPARGPPARDPPARAIAPPCCR5
SCHEMBL14790110 0.73 IAPP (0.57) IAPPPOLBGAACYP3A4ADRB2
SCHEMBL29388330 0.73 IAPP (0.57) IAPPPOLBGAACYP3A4ADRB2
SCHEMBL12556406 0.72 IAPP (0.56) IAPPCCR5POLBGAALMNA
SCHEMBL21203290 0.71 IAPP (0.72) IAPPCCR5POLBGAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200392223-A1 IL-17A ACTIVITY INHIBITOR AND USE THEREOF TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2020-12-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200392223-A1 IL-17A ACTIVITY INHIBITOR AND USE THEREOF IL17A, IL23R, IL15RA PPARG 1058/4885PPARD 2704/4885PPARA 2046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback